Innovation Pharmaceuticals Inc (IPIX)

[JB3729]

I agree and feel this PR is the most significant yet -

Not sure why the PR is being overly downplayed. This was the first trial update in 7 weeks and the news is awesome!

The ASCO meeting gives Cellceutix an opportunity to provide a comprehensive update on the latest data from the Kevetrin clinical trials to shareholders and leaders in the scientific community as well as time for interaction with others about possible future collaborations and studies. IMO, this exudes confidence that the trials will run smoothly and produce the desired results.

Dr. Krishna Menon, Chief Scientific Officer at Cellceutix, commented, “We are still at the early stages of the clinical trial. To date, we have not observed any dose limiting toxicities. Initial pharmacokinetic (PK) data from the clinical trial has been received and is consistent with the animal data, which is a very optimistic sign moving forward. Additional information on these PK studies will be forthcoming at ASCO. We are now looking forward to receiving data from the p21 biomarker studies which is expected in March 2013.”

Terrific trial update and as Leo says - http://cellceutix.com/best-yet-to-come/